Why the study?
Do non-vitamin K antagonist oral anticoagulants prevent stroke and reduce bleeding compared to vitamin K antagonists in patients with atrial fibrillation and heart failure?
Do non-vitamin K antagonist oral anticoagulants prevent stroke and reduce bleeding compared to vitamin K antagonists in patients with atrial fibrillation and heart failure?
Answers are grounded in this paper and cite their sources.
This editorial highlights that NOACs are an effective and safe alternative to vitamin K antagonists for stroke prevention in patients with atrial fibrillation and heart failure.
![Graphic][1] Atrial fibrillation is one of the most common arrhythmias. Its incidence and prevalence increase with age, particularly in patients with hypertension and heart failure.1,2 Although by itself not a particularly dangerous arrhythmia, atrial fibrillation is associated with a considerable risk of stroke. Of note, patients with atrial fibrillation and heart failure have a higher risk of thrombo-embolic events and overall mortality compared with those with atrial fibrillation without heart failure as reflected by the CHA2DS2-VASc score.3,4 Importantly, the prevalence of atrial fibrillation increases with the severity of heart failure. Anticoagulation with vitamin K antagonists is more unstable in patients with concomitant atrial fibrillation and heart failure, which is an independent risk factor for reduced time under the therapeutic range. Thus the clinical review ‘ Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges ’ by Joao Pedro Ferreira and colleagues from the Centre Hospitalier Universitaire de Nancy in France is a timely update for the clinician.5 Of importance in this context, non-vitamin K antagonist oral anticoagulants, the so-called NOACs,6,7 have emerged as therapeutic alternatives for stroke prevention in patients with non-valvular atrial fibrillation, as they are at least as efficacious and safe, with less intracranial bleeding events, compared with vitamin K antagonists. The subgroup analyses of the NOAC trials in patients with atrial fibrillation and heart failure revealed that the efficacy and safety of these agents are likely to be similar to those observed in patients with atrial fibrillation without heart failure. However, many gaps in evidence exist, since heart failure has been neither consistently defined nor used as an … [1]: /embed/inline-graphic-1.gif
No takes yet. Share an insight, caveat, or question.
Thomas F. Lüscher (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: